Vera Therapeutics (NASDAQ:VERA) Hits New 52-Week Low - What's Next?

Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) hit a new 52-week low during trading on Monday . The company traded as low as $20.25 and last traded at $20.96, with a volume of 3375 shares changing hands. The stock had previously closed at $21.31.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. The Goldman Sachs Group initiated coverage on Vera Therapeutics in a report on Tuesday, January 28th. They issued a "buy" rating and a $58.00 target price for the company. Wolfe Research began coverage on shares of Vera Therapeutics in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price objective for the company. JPMorgan Chase & Co. lowered their target price on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 4th. Finally, Guggenheim boosted their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. One research analyst has rated the stock with a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $64.67.

Vera Therapeutics Trading Up 2.8 %

The firm has a market cap of $1.43 billion, a P/E ratio of -8.59 and a beta of 1.28. The company's 50 day moving average is $27.58 and its two-hundred day moving average is $37.27. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, topping analysts' consensus estimates of ($0.83) by $0.11. On average, sell-side analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Institutional Investors Weigh In On Vera Therapeutics

A number of institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC boosted its position in shares of Vera Therapeutics by 116.7% during the 4th quarter. SG Americas Securities LLC now owns 20,270 shares of the company's stock valued at $857,000 after acquiring an additional 10,916 shares in the last quarter. Lord Abbett & CO. LLC lifted its stake in Vera Therapeutics by 41.1% during the third quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company's stock worth $18,830,000 after purchasing an additional 124,197 shares during the period. Barclays PLC boosted its holdings in Vera Therapeutics by 94.1% during the third quarter. Barclays PLC now owns 85,395 shares of the company's stock valued at $3,774,000 after purchasing an additional 41,394 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Vera Therapeutics by 2.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,004,665 shares of the company's stock valued at $44,415,000 after purchasing an additional 20,223 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in shares of Vera Therapeutics in the 4th quarter worth approximately $2,948,000. Institutional investors and hedge funds own 99.21% of the company's stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.